Liver Unit, Clinical & Experimental Hepatology, Department of Internal Medicine, SG Moscati Hospital, Avellino, Avellino Contrada Amoretta 83100, Italy.
Future Oncol. 2013 Apr;9(4):485-91. doi: 10.2217/fon.12.208.
Sorafenib (SO) was the first systemic agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC); international guidelines now recommend SO as a first-line treatment in patients with unresectable HCC who are not eligible for locoregional therapies and maintain preserved liver function. However, therapy with SO may require close management to further optimize the clinical outcomes and limit the onset of adverse events (AEs). SO has been in use at our Liver Unit (Avellino, Italy) for over 4 years, and in that time 85 patients with HCC have been treated with SO. Here we describe how patients with HCC are managed with SO in our unit where management is based on three pivotal strategies: targeted patient selection; use of dose escalation to increase compliance and reduce AEs; and adoption of measures to prevent and manage AEs and to provide open access for patients.
索拉非尼（SO）是第一个在晚期肝细胞癌（HCC）患者的总生存期方面显示出显著改善的系统治疗药物；国际指南现在建议将 SO 作为不适合局部区域治疗且保持肝功能正常的不可切除 HCC 患者的一线治疗药物。然而，SO 的治疗可能需要密切管理，以进一步优化临床结果并限制不良事件（AE）的发生。SO 在我们的肝脏科（意大利阿韦利诺）已经使用了 4 年多，在此期间，有 85 名 HCC 患者接受了 SO 治疗。在这里，我们描述了我们科室是如何对 HCC 患者进行 SO 管理的，管理的基础是三个关键策略：有针对性的患者选择；使用剂量递增来提高依从性并减少 AE；以及采取措施预防和管理 AE，并为患者提供开放通道。
